Leading broker says Pro Medicus (ASX:PME) share price is a buy

It could be time to buy Pro Medicus shares…

| More on:
Two brokers pointing and analysing a share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Pro Medicus shares have been upgraded by the team at Bell Potter
  • It made the move on valuation grounds following a recent pullback
  • Although Bell Potter has reduced its price target, it still sees plenty of upside

The Pro Medicus Limited (ASX: PME) share price has started the week in the red.

In afternoon trade, the health imaging technology company's shares are down slightly to $45.50.

This means the Pro Medicus share price is now down 28% since the start of the year.

Is the Pro Medicus share price good value?

One leading broker that sees a lot of value in the Pro Medicus share price is Bell Potter.

According to a note, the broker has upgraded the company's shares to a buy rating with a trimmed price target of $55.00.

Based on the current Pro Medicus share price, this implies potential upside of 21% over the next 12 months.

What did the broker say?

Bell Potter made the move on valuation grounds. It believes the "recent route in high growth technology and healthcare stocks has created an attractive entry point for some high quality names including PME."

Particularly given its expectation for Pro Medicus to deliver double digit revenue and earnings growth later this month when it releases its half year results.

In addition, the broker is positive on the future and believes that "as imaging technology grows in complexity (and data size) the use case for the Visage technology continues to become more compelling."

And while Morgans has trimmed its price target, it feels this is appropriate following the recent market selloff and notes that it still offers major upside potential.

The broker explained: "Our target price is amended to $55.00 from $62.00. The target price is determined from a hybrid model of a DCF and a capitalised earnings model. We applied a 10% discount to the capitalisation multiple of revenues in order to adjust the target price. In our view this is appropriate following the recent market correction across both healthcare and information technology sectors."

"In our view the current market price represents an attractive entry point to this very high quality healthcare technology play. We upgrade our recommendation from Hold to Buy. Changes to earnings are not material," it concluded.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Pro Medicus Ltd. The Motley Fool Australia owns and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two doctors smile as they sit together at a desk looking at a patient's x-ray.
Healthcare Shares

Why Macquarie rates this ASX All Ords medical imaging stock a buy

The broker maintains its outperform rating on the stock.

Read more »

A man in a hospital bed on a drip gives a thumbs up sign.
Healthcare Shares

Macquarie predicts 86% upside for this ASX 200 healthcare stock

Shares could almost double over the next 12 months, according to the broker.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares?

Novo Nordisk just lost $100 billion in market value.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 11% today

Let's see why investors are bidding this stock higher on Wednesday.

Read more »

stockmarket graphic in background with man looking at stockmarket on phone
Healthcare Shares

CSL shares are a buy – UBS

This expert is optimistic on what the business can achieve despite headwinds.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »